Biogen's (BIIB) dominance in multiple sclerosis drove sales 50% higher in the first quarter, as Tecfidera successfully expanded market share.
Todd Campbell, The Motley Fool, The Motley Fool
Thu, 04/24/2014 - 6:30am
Biogen's (BIIB) dominance in multiple sclerosis drove sales 50% higher in the first quarter, as Tecfidera successfully expanded market share.